Research and Clinical Trials

Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) vs Avonex® in Patients with Relapsing-Remitting Multiple Sclerosis
Brief Description  
The main purpose of the study is to see if the drug DAC HYP (daclizamab) is more effective than Avonex® in the treatment of MS. This study will also allow researchers to learn more about the safety of long-term treatment with DAC HYP in people with MS. The sponsor also wants to see if DAC HYP treatment affects the number and/or size of the MS lesions (abnormal spots) in the
Who may be Eligible  
The study is open to men and women ages 18 through 55, who have been diagnosed with Relapsing Remitting MS.
IRB Number  
Principal Investigator  
Conway, Jill

For More Information, Contact  Rita  M, Rouse
Phone:  (704) 446-1902  Fax:  (704) 446-6208  
Address:1010 Edgehill Road North Charlotte, NC 28207